Deferiprone (Deferiprone) Patent Expiration, LOE Window & CMS Spending

Deferiprone (Deferiprone) by Hikma Pharmaceuticals: Multi-Source Generic Molecule, 3 AB generics, $10.8M 2024 CMS Part D & Medicaid spend, and $6,976 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$10.8M
2024 Medicare Part D Spend$7.3M
2024 Medicaid Spend$3.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,976 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.